Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.65 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.65 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18095861 | 1.00 | CTNNB1 (0.65) | CTNNB1TCF7L2AKR1B1PTPN1POLB | |
| SCHEMBL18102989 | 1.00 | CTNNB1 (0.65) | CTNNB1TCF7L2AKR1B1PTPN1POLB | |
| SCHEMBL19999075 | 0.91 | CTNNB1 (0.59) | CTNNB1TCF7L2AKR1B1PTPN1POLB | |
| SCHEMBL18095816 | 0.90 | CTNNB1 (0.58) | CTNNB1TCF7L2AKR1B1PTPN1POLB | |
| SCHEMBL18095817 | 0.90 | CTNNB1 (0.58) | CTNNB1TCF7L2AKR1B1PTPN1POLB | |
| SCHEMBL18103066 | 0.90 | CTNNB1 (0.58) | CTNNB1TCF7L2AKR1B1PTPN1POLB | |
| SCHEMBL12008777 | 0.89 | CTNNB1 (0.81) | CTNNB1TCF7L2POLBKMT2AMEN1 | |
| SCHEMBL20534555 | 0.89 | AKR1B1 (0.61) | AKR1B1 | |
| SCHEMBL20534556 | 0.89 | AKR1B1 (0.61) | AKR1B1 | |
| SCHEMBL21773419 | 0.89 | AKR1B1 (0.61) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3374027-A1 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS | The Trustees of Columbia University in the City of New York (US) | 2018-09-19 | — | — | EP | claimed |
| WO-2017083859-A1 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-05-18 | — | — | WO | claimed |
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | UNIVERSITY OF MIAMI (US) | 2019-12-10 | — | — | US | disclosed |
| EP-3374027-A1 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS | The Trustees of Columbia University in the City of New York (US) | 2018-09-19 | — | — | EP | disclosed |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| EP-3282846-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | University of Miami (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2017083859-A1 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-05-18 | — | — | WO | disclosed |
| WO-2016154255-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | UNIVERSITY OF MIAMI (US) | 2016-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | NOTCH1, CBFB, HES1 | CTNNB1 551/4885TCF7L2 15/4885AKR1B1 3876/4885 |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NOTCH1, CBFB, HES1 | CTNNB1 551/4885TCF7L2 15/4885AKR1B1 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.